Lipocine Inc. LPCN
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
0/9
Piotroski F — financial health
-32.69
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $2.0M | -$9.6M | — | — | $14.5M |
| 2024 | $11.2M | $8,352 | — | -$1.3M | $21.0M |
| 2023 | -$2.9M | -$16.4M | — | -$11.9M | $20.4M |
| 2022 | $500,000 | -$10.8M | — | -$12.1M | $35.6M |
| 2021 | $16.1M | -$634,399 | — | -$4.4M | $45.6M |
| 2020 | $0 | -$21.0M | — | — | $15.3M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Higuchi John W. | director | 2026-04-07 | Buy | 40,000 | $2.03 |
| Higuchi John W. | director | 2026-04-06 | Buy | 123,000 | $2.05 |
| Patel Mahesh V. | Chief Executive Officer | 2026-04-06 | Buy | 25,000 | $2.03 |
| Patel Mahesh V. | Chief Executive Officer | 2026-04-02 | Buy | 25,000 | $2.02 |
Why these scores methodology →
Piotroski F-score: 0/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -32.69 (distress)
- Working capital / assets 0.844
- Retained earnings / assets -12.313
- EBIT / assets -0.61
- Equity / liabilities 5.726
Source: SEC EDGAR filings · CIK 0001535955 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.